experience [menp]
abciximab [aapp, imft, phsu]
coronary revascularisation [topp]
overview [inpr]
Improvement [cnce]
Safety [hcpp]
Efficacy [qlco]
Percutaneous Transluminal Coronary Angioplasty [topp]
Ischaemic [ftcn]
Procedure complication [fndg]
Continue [idcn]
Patients [podg]
Pivot [medd]
Platelets [cell]
formation [biof]
Arterial thrombosis [dsyn]
Following [tmco]
coronary [bpoc]
intervention [hlca]
apparent [idcn]
Inhibitor [qlco]
Platelet aggregation [celf]
Eat [orgf]
acute [tmco]
Ischaemic [ftcn]
Complications [patf]
Restenosis [acab]
Following [tmco]
Percutaneous Transluminal Coronary Angioplasty [topp]
Attention [menp]
Focused [spco]
Platelet glycoprotein IIb-IIIa [aapp]
Integrin [aapp, imft, rcpt]
receptor [aapp, rcpt]
Mediate [socb]
Final [tmco]
Pathway [moft]
Platelet aggregation [celf]
Murine [mamm]
Monoclonal antibody [aapp, imft]
Bind [acty]
Block [patf]
receptor [aapp, rcpt]
arrested [dsyn]
binding [ftcn]
Fibrinogen [aapp, bacs, phsu]
Platelets [cell]
arrested [dsyn]
Platelet aggregation [celf]
Human [humn]
anti antibody [aapp, imft]
Murine [mamm]
responses [orga]
Antibody [aapp, celc, imft]
Modified [ftcn]
chimeric antibody [aapp, imft]
fragment [ftcn]
abciximab [aapp, imft, phsu]
c7E3 Fab [aapp, imft, phsu]
Antigen Binding Fragment [aapp, imft]
Human [humn]
Region [geoa]
Mouse [mamm]
Variable [qlco]
Region [geoa]
abciximab [aapp, imft, phsu]
Recently [tmco]
Approved [qlco]
Food and Drug Administration [hcro]
Efficacy [qlco]
Safety [hcpp]
abciximab [aapp, imft, phsu]
Recently [tmco]
COMPLETED [qlco]
Clinical Trials, Phase III [resa]
Patients [podg]
coronary angioplasty [topp]
study results [fndg]
Platelet glycoprotein IIb-IIIa [aapp]
Receptor Inhibition [celf]
abciximab [aapp, imft, phsu]
coronary [bpoc]
intervention [hlca]
Markedly [qlco]
Ischaemic [ftcn]
Events [evnt]
EPIC [lbpr]
Trial [resa]
Dose [qnco]
abciximab [aapp, imft, phsu]
Prevention [topp]
Ischaemic [ftcn]
Complications [patf]
Observed [ftcn]
reduction [npop]
Composite [qlco]
End Point [qlco]
Patients [podg]
Receive [qlco]
abciximab [aapp, imft, phsu]
Bolus [topp]
12 hour [tmco]
Infusion [topp]
Compared [acty]
Double [ftcn]
placebo [topp]
Group [idcn]
Trial [resa]
Patients [podg]
treated [topp]
abciximab [aapp, imft, phsu]
Bolus [topp]
12 hour [tmco]
Infusion [topp]
Low dose [qnco]
Heparin [bacs, carb, phsu]
reduction [npop]
Composite [qlco]
End Point [qlco]
days [tmco]
Study [mnob]
Primary Endpoint [irda]
Reduced [qlco]
days [tmco]
abciximab [aapp, imft, phsu]
therapy [ftcn]
Treatment Effect [fndg]
Observed [ftcn]
days [tmco]
reduction [npop]
acute [tmco]
Ischaemic [ftcn]
Complication [patf]
Maintained [ftcn]
abciximab [aapp, imft, phsu]
therapy [ftcn]
Carry [acty]
Increased [qnco]
Bleeding [patf]
Complications [patf]
Excess [qlco]
Haemorrhagic [qlco]
Eliminated [qlco]
strategies [menp]
reduction [npop]
Adjunctive [topp]
Heparin [bacs, carb, phsu]
Dosage [qnco]
Removal [topp]
Conservative management [topp]
vascular access [medd]
Site [spco]
Platelet glycoprotein IIb-IIIa [aapp]
Receptor Inhibition [celf]
Syndromes, Acute Coronary [dsyn]
Angina, Unstable [dsyn]
Acute myocardial infarction [dsyn]
treated [topp]
Percutaneous [spco]
intervention [hlca]
Thrombolytic Therapy [topp]
ischaemic heart disease [dsyn]
Currently [tmco]
Investigation [hlca]
Agent [chvf]
DEVICES [medd]
coronary revascularisation [topp]
Stents [medd]
Subject [grup]
Trial [resa]
Future [tmco]
Focus [spco]
Glycoprotein IIb/IIIa [aapp, imft, rcpt]
Inhibition [menp]
Generation [tmco]
Orally [spco]
Active [ftcn]
Agent [chvf]
